Current practice and surgical outcomes of neoadjuvant chemotherapy for early breast cancer: UK NeST study.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Neoadjuvant chemotherapy (NACT) is increasingly being used to treat early breast cancer, and offers several advantages, including reducing the extent of breast and axillary surgery, and providing an in vivo assessment of tumour sensitivity to treatment1–4. Clinical trials have identified tumour subgroups with high rates of pCR. A pCR can be achieved in 45–90 per cent of human epidermal growth factor receptor 2-positive (HER2+) tumours and triple-negative breast cancer (TNBC), but the rate in oestrogen receptor-positive (ER+)/HER2-negative (HER2–) breast cancer remains below 10 per cent3,5. Historically, increasing pCR rates following NACT have not translated into more breast-conserving surgery (BCS), but more recent data suggest that NACT can result in surgical downstaging6.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1365-2168